Latest news with #cognitiveEnhancement
Yahoo
23-06-2025
- Health
- Yahoo
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer's disease
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB'S POTENTIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE CLINICAL PHASE 2B/3 STUDY SHOWING COGNITIVE IMPROVEMENT UNDER MASITINIB TREATMENT PHASE 3 CLINICAL STUDY WITH MASITINIB AS A DISEASE-MODIFYING THERAPY FOR ALZHEIMER'S DISEASE HAS BEEN AUTHORIZED BY THE FDA AND KEY EU COUNTRIES Paris, June 23, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that a new peer-reviewed study from an independent research team based in China (Guangdong Pharmaceutical University and Sun Yat-sen University) presents new evidence showing that masitinib offers a promising new approach to treating Alzheimer's disease, specifically the most common form, sporadic Alzheimer's disease (sAD), which accounts for over 95% of all cases. Masitinib is a highly innovative drug for Alzheimer's disease because unlike the majority of drug development research in this indication, masitinib targets the brain's innate immune system, including mast cells and microglia. The positioning of masitinib as a treatment of Alzheimer's disease is also different from other drugs. New evidence from peer-reviewed study This new publication is accessible online from the Neuroscience Letters journal website at: [1] In the study, researchers used a well-established mouse model that mimics the cognitive and behavioral symptoms of human sAD. When treated with masitinib, the mice showed marked improvements in memory, learning, sense of smell, and anxiety-like behaviors, all of which are early indicators of Alzheimer's progression. The research also revealed that masitinib: • Reduced toxic brain proteins such as hyperphosphorylated Tau. • Alleviated synaptic dysfunction and morphological damage, i.e., it protected synapses, which are essential for brain cell communication. • Suppressed microglial activation, which in turn inhibited the NF-κB/NLRP3/caspase-1 signaling axis, a key inflammatory signaling cascade linked to Alzheimer's disease, thereby suppressing inflammation in the brain of sAD mice. The authors emphasized that this is the first study to demonstrate that masitinib attenuates sporadic Alzheimer's disease pathology through dual mechanisms of cognitive enhancement and neuroprotection. Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France said, 'These new, independent findings provide strong evidence supporting masitinib as a promising disease-modifying therapy for sporadic Alzheimer's disease and perfectly compliment previously published clinical and preclinical data for masitinib in this indication.' New data from phase 2B/3 study in patients with mild Alzheimer's disease It has previously been shown that masitinib enhances cognitive function and synaptic integrity in a familial Alzheimer's disease mouse model [2]. Moreover, randomized, placebo-controlled, phase 2 and phase 2B/3 studies demonstrated that masitinib (4.5 mg/kg/day) can effectively delay or mitigate the progression of dementia [3,4]. Clinical and preclinical study findings have also been summarized in a review article [5], with the authors concluding that 'all research studies revealed positive effects concerning the cognitive functions in Alzheimer's disease and generally with good safety and tolerability'. New analysis from the completed phase 2B/3 study (AB09004), shows that masitinib treatment may not only slow down worsening of cognition in patients with mild Alzheimer's disease, but actually improves it over the treatment period of 24 weeks. Indeed, study AB09004 included patient with both mild and moderate AD (MMSE [12 - 25]). In the overall study population, which included patient with both mild and moderate AD (MMSE [12 - 25]), masitinib 4.5 mg/kg/day plus standard of care (memantine and anticholinesterase) demonstrated a significant reduction in cognitive impairment (ADAS-Cog LS Mean Diff = -2.15; p=0.0003) compared with standard of care alone. However, the clinical benefit on ADAS-Cog was greater in patients with mild impairment (LS Mean Diff = -2.89 ; p=0.0008) than in patients with moderate impairment (LS Mean Diff = -1.74; p=0.0284). Notably, there was a meaningful improvement in cognitive function between baseline and week 24 in the mild AD subgroup under masitinib treatment (LS Mean = -2.47), while it remained stable in the control arm (LS Mean = -0.42), as presented in the table below. ADAS-COG Change from Baseline to Week 24 N LS Mean LS Mean Diff.(97.51% CI) p-value Mild and moderate AD patients Masitinib 4.5 mg/kg/day + SoC 182 -1.45 -2.15(-3.48, -0.81) 0.0003 Placebo + SoC 176 0.69 ADAS-COG Change from Baseline to Week 24 N LS Mean LS Mean Diff.(97.51% CI) p-value Mild patients [MMSE (21-25)] Masitinib 4.5 mg/kg/day + SoC 63 -2.47 -2.89(-4.80, -0.99) 0.0008 Placebo + SoC 61 0.42 Moderate patients [MMSE (12-20)] Masitinib 4.5 mg/kg/day + SoC 119 -1.04 -1.74(-3.52, 0.04) 0.0284 Placebo + SoC 115 0.70 SoC = Standard of care = memantine and anticholinesteraseNote : Negative change in LS Mean of ADAS-COG means an improvement of cognition. Positive change in LS Mean of ADAS-COG means a worsening of cognition. Authorized phase 3 to support New Drug Application in case of success AB Science previously received an Investigational New Drug (IND) approval letter from the FDA and similar authorizations from several European countries to initiate Phase III study (AB21004) in patients with Alzheimer's disease. Study AB21004 is a randomized, double-blind phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild Alzheimer's disease, as an add-on therapy to standard of care, cholinesterase inhibitors and/or memantine. The study will enroll 600 patients. The objective of study AB21004 is to confirm results from the first phase 2B/3 study, AB09004, which showed that masitinib administered at 4.5 mg/kg/day significantly slowed cognitive deterioration relative to placebo and also reduced loss of functional ability in activities of daily living in the targeted AD population. Study AB21004 will evaluate the effect of masitinib on absolute change from baseline in cognition (ADAS-Cog-11) as primary endpoint and integrated AD rating scale (iADRS) and daily living (ADCS-ADL) as secondary endpoints. Expected patent protection until 2041 Based on the results from AB09004 study, AB Science filed a patent application relating to methods of treating Alzheimer's disease (i.e. a medical use patent) with its lead compound masitinib (WO2022129410A1). If granted, this patent will provide intellectual property protection for masitinib in this indication until 2041. A similar strategy was successfully applied in Amyotrophic Lateral Sclerosis, with medical use patent for masitinib in ALS being granted worldwide (press release dated June 1st 2023). References : Jia K, Shen Q, Zhang Z, et al. Masitinib attenuates neuropathological changes in acrolein-induced sAD mouse model via NF-κB/NLRP3/Caspase-1 signaling pathway. Neurosci Lett. Volume 862, 27 July 2025, 138300. Published online June 10, 2025. Li T, Martin E, Abada YS, et al. Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1339-1345. doi:10.3233/JAD-200466 Dubois B, López-Arrieta J, Lipschitz S, et al. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial [published correction appears in Alzheimers Res Ther. 2023 Apr 22;15(1):85. doi: 10.1186/s13195-023-01230-9.]. Alzheimers Res Ther. 2023;15(1):39. Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011;3(2):16. Published 2011 Apr 19. doi:10.1186/alzrt75 Ettcheto M, Cano A, Sanchez-López E, et al. Masitinib for the treatment of Alzheimer's disease. Neurodegener Dis Manag. 2021;11(4):263-276. doi:10.2217/nmt-2021-0019 About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ Attachment Alz sAD Model PreClin vENG VFError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
18-06-2025
- Health
- Forbes
5 Surprising Ways Too Much Screen Time Impacts Your Brain
Excessive screen time can impact brain health and productivity, making intentional breaks more ... More important than ever. The average American now spends 12 hours and 36 minutes staring at screens every day, with approximately 104 million people exposed to excessive screen time of seven or more hours daily. While we often focus on physical symptoms like eye strain and neck pain, neuroscience research reveals that excessive screen time is literally reshaping our brains in surprising ways. "The negative effects of screen time are insidious because you can't see what's happening in your brain as you're staring at the screen," explains Maris Loeffler, member of the Stanford Lifestyle Medicine Cognitive Enhancement pillar. "If you scrolled on your phone in bed for an hour just one morning, the negative impacts would be minimal. But if it becomes a habit, day after day, month after month, this behavior can take a toll." Here are five scientifically-backed ways excessive screen time is impacting your brain, along with actionable workplace strategies to protect your mental acuity. One of the most astonishing discoveries in recent neuroscience research is that excessive screen time can lead to physical changes in the brain's structure. Studies show that in adults aged 18-25, excessive screen time can cause thinning of the cerebral cortex, the brain's outermost layer responsible for essential brain functions like memory and problem-solving. Your cerebral cortex is your brain's command center, orchestrating everything from complex reasoning to creative thinking. When this region becomes thinner due to excessive screen exposure, it can impact your ability to focus, make decisions and process information effectively. Implement the 20-20-20 rule recommended by The American Academy of Ophthalmology throughout your workday. Every 20 minutes, look at something 20 feet away for at least 20 seconds. Schedule this as recurring calendar reminders if needed. Additionally, negotiate "cortex recovery" breaks with your employer. Brief 10- to 15-minute breaks every two hours can boost productivity. Use these breaks for activities like brainstorming sessions, walking meetings or reviewing printed materials rather than staying glued to your monitor. Gray matter is your brain's essential tissue responsible for everything from movement to emotions. While gray matter naturally decreases with age, research indicates that adults who engage in excessive screen time have significantly lower gray matter volume compared to their peers. This premature shrinkage is concerning because gray matter houses the majority of your brain's neuronal cell bodies. When you lose gray matter volume ahead of schedule, you're accelerating cognitive aging, which can impact your memory, emotional regulation and overall mental sharpness. To protect and build your gray matter at work, consider these neuroscience-backed strategies: • Take walking meetings: Replace video calls with phone calls while walking, or suggest walking discussions for one-on-one meetings to combine exercise with collaboration. • Prioritize in-person interactions: Choose face-to-face conversations over Slack messages when possible, attend networking events and participate in team-building activities. • Engage in professional development: Attend workshops, take online courses during designated learning time or join professional associations that require active participation and new skill development. The blue light emitted by screens doesn't just strain your eyes; it also affects your sleep. Research demonstrates that screen light can delay the release of melatonin from the brain's pineal gland, disrupting the body's natural circadian rhythm and making it difficult to fall asleep and achieve restorative sleep cycles. When your circadian rhythm is consistently disrupted, it creates a series of problems that neuroscience research has linked to impaired cognitive performance. Poor sleep quality impairs memory consolidation, reduces cognitive performance and can even contribute to mood disorders and anxiety. To protect your sleep and circadian rhythm: • Set clear boundaries: Negotiate with your employer to avoid late-night emails and establish "off-hours" communication policies. • Use protective technology: If you must work late, use blue light-blocking glasses or enable night mode on all devices. • Create a shutdown ritual: Physically close your laptop, turn off notifications and transition to non-screen activities like reviewing tomorrow's priorities on paper. • Propose flexible hours: Consider work schedules that align with your natural circadian rhythm for peak performance. "One of the biggest issues with picking up the phone right away in the morning is that when you have an object close to your face, it's registered as a threat," explains Loeffler. "You wouldn't want to wake up and look a bear in the face every morning. On a physiological level, it's the same thing." When you immediately reach for your phone upon waking and dive into emails, you jolt your nervous system and trigger a fight-or-flight response before you're fully awake. This creates a pattern where your brain defaults to hypervigilance and anxiety throughout the day, making it harder to relax, focus and think clearly. Implement a screen-free first hour of your day. Instead of checking emails immediately, start with activities that regulate your nervous system, like exercise, meditation or preparing a healthy breakfast. Arrive at work early to settle in without the immediate pressure of emails and notifications. Use this time to plan your day, organize your workspace or have informal conversations with colleagues. This approach helps you start work from a calm, focused state rather than reactive stress mode. Research indicates that adults who watch television for five hours or more daily may have an increased risk of developing diseases like dementia, stroke or Parkinson's. This connection likely stems from the combination of factors we've already discussed: reduced gray matter, disrupted sleep patterns, chronic stress activation and the sedentary lifestyle that often accompanies excessive screen time. When these factors compound over years or decades, they can accelerate cognitive decline and increase vulnerability to serious neurological conditions. Take a comprehensive approach to brain health in your professional life: • Seek cognitive challenges: Volunteer for projects requiring strategic thinking, problem-solving and creative solutions, or lead cross-functional teams and mentor colleagues. • Champion workplace wellness: Propose initiatives like lunchtime walking groups, meditation sessions or stress management workshops incorporating neuroscience-based techniques. • Advocate for health support: Push for ergonomic workstations and regular health screenings through your employee benefits. Remember that your brain is remarkably adaptable. By taking control of your screen time and protecting your cognitive health, you can actually rewire your brain's neural pathways, reduce the risk of mental decline and create a healthier relationship with technology that advances rather than hinders your professional success.
Associated Press
23-05-2025
- Business
- Associated Press
U.S. Nootropics Market Trends Analysis and Growth Forecasts, 2025-2030 - Workplace and Academic Pressures Propel Consumer Shift Toward Cognitive Supplements
DUBLIN--(BUSINESS WIRE)--May 23, 2025-- The 'U.S. Nootropics Market Size, Share & Trends Analysis Report by Product (Natural, Synthetic), Form (Powder, Drinks, Gummies), Application, Distribution Channel, with Growth Forecasts, 2025-2030" report has been added to offering. The U.S. Nootropics Market was valued at USD 2.81 Billion in 2024, and is projected to reach USD 4.68 Billion by 2030, rising at a CAGR of 9.00% This robust expansion is primarily fueled by the increasing consumer awareness and acceptance of cognitive enhancement products. Heightened societal focus on mental performance in demanding professional and academic environments, coupled with a growing aging population concerned about cognitive decline, significantly boosts demand. Furthermore, the expanding application of nootropics beyond just cognitive enhancement, encompassing areas like mood support and stress reduction, broadens their market appeal and attracts a more diverse consumer base. Natural products held a major share in 2024. This is due to consumer preferences for health and wellness solutions perceived as gentle and safe. This preference is strongly influenced by the association of 'natural' with fewer synthetic chemicals and potentially milder side effects. The effective marketing and branding of natural nootropics, capitalizing on the broader 'clean label' and plant-based trends, further propelled their market dominance by resonating strongly with health-conscious consumers seeking cognitive enhancement solutions aligned with natural and holistic wellness philosophies. The drinks segment held the largest share in 2024. This can be attributed to their inherent convenience and accessibility for consumers. Ready-to-drink nootropic beverages seamlessly integrate into daily routines, offering an easily consumable format compared to capsules or powders. Furthermore, drinks often provide a perception of faster absorption and quicker onset of effects, aligning with the immediate cognitive enhancement sought by many nootropic users. The beverage format also allows for greater flexibility in flavor profiles and taste masking, enhancing palatability and broadening appeal to a wider consumer base. Cognitive enhance held the largest share in the U.S. nootropics industry in 2024. The growth addresses the core and most widely recognized application of these substances. The fundamental driver is the increasing societal emphasis on optimal mental performance in various aspects of life, from demanding professional careers to competitive academic pursuits. Individuals are actively seeking solutions to improve focus, memory, attention span, and learning capabilities to gain a competitive edge and enhance productivity. Major market players include Reckitt Benckiser Group PLC (Schiff RB Health (US) LLC); Unilever Onnit Labs, Inc.; Amway; GNC Holdings, LLC; NeuroGum, Inc.; Qualia Life Sciences, LLC; NOW Foods.; Performance Lab USA Corp.; Natural Stacks; BrainMD Health; and Nootropics Depot. Various steps are adopted by these companies, including new product launches, partnerships, mergers & acquisitions, global expansion, and others to gain more share of the market. U.S. Nootropics Market Report Highlights Why Should You Buy This Report? Companies Featured Key Attributes: Key Topics Covered: Chapter 1. Methodology and Scope Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Product Outlook 2.3. Form Outlook 2.4. Application Outlook 2.5. Distribution Channel Outlook Chapter 3. U.S. Nootropics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.2. Industry Value Chain Analysis 3.2.1. Raw Material Outlook 3.2.2. Manufacturing & Technology Outlook 3.2.3. Profit Margin Analysis 3.3. Market Dynamics 3.3.1. Market Driver Analysis 3.3.2. Market Restraint Analysis 3.3.3. Market Opportunities 3.3.4. Market Challenges 3.4. Industry Analysis - Porter's Five Forces Analysis 3.5. Market Entry Strategies Chapter 4. U.S. Nootropics Market: Product Estimates & Trend Analysis 4.1. U.S. Nootropics Market, by Product: Key Takeaways 4.2. Product Movement Analysis & Market Share, 2024 & 2030 4.3. Market Estimates & Forecasts, by Product, 2018-2030 (USD Million) 4.3.1. Natural 4.3.1.1. Market estimates and forecast, 2018-2030 (USD Million) 4.3.2. Synthetic 4.3.2.1. Market estimates and forecast, 2018-2030 (USD Million) Chapter 5. U.S. Nootropics Market: Form Estimates & Trend Analysis 5.1. U.S. Nootropics Market, by Form: Key Takeaways 5.2. Form Movement Analysis & Market Share, 2024 & 2030 5.3. Market Estimates & Forecasts, by Form, 2018-2030 (USD Million) 5.3.1. Capsules/Tablets 5.3.2. Powder 5.3.3. Drinks 5.3.4. Gummies 5.3.5. Others (Liquid, patches, and novel delivery methods) Chapter 6. U.S. Nootropics Market: Application Estimates & Trend Analysis 6.1. U.S. Nootropics Market, by Application: Key Takeaways 6.2. Application Movement Analysis & Market Share, 2024 & 2030 6.3. Market Estimates & Forecasts, by Application, 2018-2030 (USD Million) 6.3.1. Cognitive Enhance 6.3.2. Mood & Stress Management 6.3.3. Sleep Optimization 6.3.4. Energy & Physical Performance 6.3.5. Others (Microcirculation, Anti-Aging & Longevity, Social Anxiety & Confidence Enhancement, Creativity boosting) Chapter 7. U.S. Nootropics Market: Distribution Channel Estimates & Trend Analysis 7.1. U.S. Nootropics Market, by Distribution Channel: Key Takeaways 7.2. Distribution Channel Movement Analysis & Market Share, 2024 & 2030 7.3. Market Estimates & Forecasts, by Form, 2018-2030 (USD Million) 7.3.1. Offline 7.3.2. Online Chapter 8. Competitive Analysis 8.1. Recent developments & impact analysis, by key market participants 8.2. Company Categorization 8.3. Participant's Overview 8.4. Financial Performance 8.5. Product Benchmarking 8.6. Company Market Share Analysis, 2024 (%) 8.7. Company Heat Map Analysis 8.8. Strategy Mapping 8.9. Company Profiles 8.9.1. Company Overview 8.9.2. Financial Performance 8.9.3. Product Portfolios 8.9.4. Strategic Initiatives For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: FITNESS & NUTRITION HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 05/23/2025 09:26 AM/DISC: 05/23/2025 09:25 AM
Yahoo
22-05-2025
- Business
- Yahoo
U.S. $4.68 Bn Nootropics Market Growth Forecasts to 2030: Expanding Use Cases Push Nootropics Beyond Brain Boosting to Stress and Mood Support
Robust expansion is fueled by the increasing consumer awareness and acceptance of cognitive enhancement products. Heightened societal focus on mental performance in demanding professional and academic environments, coupled with a growing aging population concerned about cognitive decline, significantly boosts demand. Furthermore, the expanding application of nootropics beyond just cognitive enhancement, encompassing areas like mood support and stress reduction, broadens their market appeal and attracts a more diverse consumer base. U.S. Nootropics Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "U.S. Nootropics Market Size, Share & Trends Analysis Report by Product (Natural, Synthetic), Form (Powder, Drinks, Gummies), Application, Distribution Channel, with Growth Forecasts, 2025-2030" report has been added to U.S. Nootropics Market was valued at USD 2.81 Billion in 2024, and is projected to reach USD 4.68 Billion by 2030, rising at a CAGR of 9.00% This robust expansion is primarily fueled by the increasing consumer awareness and acceptance of cognitive enhancement products. Heightened societal focus on mental performance in demanding professional and academic environments, coupled with a growing aging population concerned about cognitive decline, significantly boosts demand. Furthermore, the expanding application of nootropics beyond just cognitive enhancement, encompassing areas like mood support and stress reduction, broadens their market appeal and attracts a more diverse consumer base. Natural products held a major share in 2024. This is due to consumer preferences for health and wellness solutions perceived as gentle and safe. This preference is strongly influenced by the association of "natural" with fewer synthetic chemicals and potentially milder side effects. The effective marketing and branding of natural nootropics, capitalizing on the broader 'clean label' and plant-based trends, further propelled their market dominance by resonating strongly with health-conscious consumers seeking cognitive enhancement solutions aligned with natural and holistic wellness drinks segment held the largest share in can be attributed to their inherent convenience and accessibility for consumers. Ready-to-drink nootropic beverages seamlessly integrate into daily routines, offering an easily consumable format compared to capsules or powders. Furthermore, drinks often provide a perception of faster absorption and quicker onset of effects, aligning with the immediate cognitive enhancement sought by many nootropic users. The beverage format also allows for greater flexibility in flavor profiles and taste masking, enhancing palatability and broadening appeal to a wider consumer enhance held the largest share in the U.S. nootropics industry in 2024. The growth addresses the core and most widely recognized application of these substances. The fundamental driver is the increasing societal emphasis on optimal mental performance in various aspects of life, from demanding professional careers to competitive academic pursuits. Individuals are actively seeking solutions to improve focus, memory, attention span, and learning capabilities to gain a competitive edge and enhance market players include Reckitt Benckiser Group PLC (Schiff RB Health (US) LLC); Unilever Onnit Labs, Inc.; Amway; GNC Holdings, LLC; NeuroGum, Inc.; Qualia Life Sciences, LLC; NOW Foods.; Performance Lab USA Corp.; Natural Stacks; BrainMD Health; and Nootropics Depot. Various steps are adopted by these companies, including new product launches, partnerships, mergers & acquisitions, global expansion, and others to gain more share of the market.U.S. Nootropics Market Report Highlights Based on product, the synthetic segment is estimated to grow at a substantial CAGR over the forecast period. The capacity for targeted cognitive enhancement and precise formulations have stimulated the growth. Ongoing research enables the development of novel synthetic compounds with specific mechanisms of action and enhanced potency compared to natural extracts. Synthetic production allows for greater control over purity and consistency, potentially leading to more predictable and reliable effects, appealing to users seeking optimized and tailored cognitive benefits. Based on form, the gummies segment is anticipated to grow at a significant CAGR over the forecast period, driven by the appealing and convenient format of gummies. Gummies offer a palatable and enjoyable consumption experience, masking the potential bitterness of ingredients and resembling popular confectionery. Based on application, the sleep optimization segment is anticipated to grow at a faster CAGR over the forecast period. The increasing recognition of sleep's crucial role in cognitive function and overall well-being and rising rates of sleep disorders and stress-induced sleep issues are driving demand for natural sleep aids. Based on distribution channel, the online segment is anticipated to grow at a faster CAGR over the forecast period due to enhanced accessibility and convenience. They offer a wider selection of nootropics compared to brick-and-mortar stores, often at competitive prices due to reduced overhead. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Companies Featured Reckitt Benckiser Group PLC (Schiff RB Health (US) LLC) Unilever Onnit Labs, Inc. Amway GNC Holdings, LLC NeuroGum, Inc. Qualia Life Sciences, LLC NOW Foods. Performance Lab USA Corp. Natural Stacks BrainMD Health Nootropics Depot Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.81 Billion Forecasted Market Value (USD) by 2030 $4.68 Billion Compound Annual Growth Rate 9.0% Regions Covered United States Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Product Outlook2.3. Form Outlook2.4. Application Outlook2.5. Distribution Channel OutlookChapter 3. U.S. Nootropics Market Variables, Trends & Scope3.1. Market Lineage Outlook3.2. Industry Value Chain Analysis3.2.1. Raw Material Outlook3.2.2. Manufacturing & Technology Outlook3.2.3. Profit Margin Analysis3.3. Market Dynamics3.3.1. Market Driver Analysis3.3.2. Market Restraint Analysis3.3.3. Market Opportunities3.3.4. Market Challenges3.4. Industry Analysis - Porter's Five Forces Analysis3.5. Market Entry StrategiesChapter 4. U.S. Nootropics Market: Product Estimates & Trend Analysis4.1. U.S. Nootropics Market, by Product: Key Takeaways4.2. Product Movement Analysis & Market Share, 2024 & 20304.3. Market Estimates & Forecasts, by Product, 2018-2030 (USD Million)4.3.1. Natural4.3.1.1. Market estimates and forecast, 2018-2030 (USD Million)4.3.2. Synthetic4.3.2.1. Market estimates and forecast, 2018-2030 (USD Million)Chapter 5. U.S. Nootropics Market: Form Estimates & Trend Analysis5.1. U.S. Nootropics Market, by Form: Key Takeaways5.2. Form Movement Analysis & Market Share, 2024 & 20305.3. Market Estimates & Forecasts, by Form, 2018-2030 (USD Million)5.3.1. Capsules/Tablets5.3.2. Powder5.3.3. Drinks5.3.4. Gummies5.3.5. Others (Liquid, patches, and novel delivery methods)Chapter 6. U.S. Nootropics Market: Application Estimates & Trend Analysis6.1. U.S. Nootropics Market, by Application: Key Takeaways6.2. Application Movement Analysis & Market Share, 2024 & 20306.3. Market Estimates & Forecasts, by Application, 2018-2030 (USD Million)6.3.1. Cognitive Enhance6.3.2. Mood & Stress Management6.3.3. Sleep Optimization6.3.4. Energy & Physical Performance6.3.5. Others (Microcirculation, Anti-Aging & Longevity, Social Anxiety & Confidence Enhancement, Creativity boosting)Chapter 7. U.S. Nootropics Market: Distribution Channel Estimates & Trend Analysis7.1. U.S. Nootropics Market, by Distribution Channel: Key Takeaways7.2. Distribution Channel Movement Analysis & Market Share, 2024 & 20307.3. Market Estimates & Forecasts, by Form, 2018-2030 (USD Million)7.3.1. Offline7.3.2. OnlineChapter 8. Competitive Analysis8.1. Recent developments & impact analysis, by key market participants8.2. Company Categorization8.3. Participant's Overview8.4. Financial Performance8.5. Product Benchmarking8.6. Company Market Share Analysis, 2024 (%)8.7. Company Heat Map Analysis8.8. Strategy Mapping8.9. Company Profiles8.9.1. Company Overview8.9.2. Financial Performance8.9.3. Product Portfolios8.9.4. Strategic InitiativesFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Nootropics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
